Table 2 The survival Rate of Proliferation of MKN45 gastric Cells by Baicalin Combined with VCR, ADM, and 5-FU Intervention (\({\overline{\text{x}}}\) ± s, n = 6, %).

From: Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis

Groups

Control

0.01 × PPC

0.1 × PPC

1 × PPC

10 × PPC

100 × PPC

ADM

100 ± 4.52

96.14 ± 10.28

87.44 ± 5.77

63.66 ± 2.46

67.11 ± 5.51

47.61 ± 3.51

ADM + Baicalin 200uM

100 ± 3.67

63.62 ± 3.93a

61.24 ± 4.38a

56.25 ± 1.88a

45.64 ± 3.21a

29.83 ± 5.17a

5-FU

100 ± 1.56

84.38 ± 7.24

78.89 ± 3.74

75.55 ± 1.91

69.43 ± 1.7

39.68 ± 3.17

5-FU + Baicalin 200uM

100 ± 2.14

65.06 ± 8.78a

58.84 ± 2.26a

56.58 ± 3.11a

49.22 ± 4.12a

33.79 ± 3.67a

VCR

100 ± 1.54

72.93 ± 2.15

50.73 ± 2.36

41.7 ± 1.78

36.37 ± 2.59

24.13 ± 3.49

VCR + Baicalin 200uM

100 ± 3.49

56.15 ± 3.2a

38.63 ± 1.18a

34 ± 2.71a

27.96 ± 3.29a

15.91 ± 2.21a

  1. Compared with single VCR, ADM, 5-FU at the same concentration.
  2. aP < 0. 01.